Purpose: Following safety concerns regarding trimetazidine, the European Medicines Agency (EMA) recommended restrictions on its use. Our objective was to determine the impact of regulatory actions on trimetazidine utilization in Portugal.
Methods: Retrospective interrupted time-series analysis of monthly ambulatory pharmacy reimbursement records for the Portuguese National Health Service between January 2006 and December 2015. Regulatory actions were identified by searching the EMA, Portuguese Medicines Authority, and European Commission's websites. Concurrent factors in the same period were also identified. The main outcome was the dispensing of trimetazidine-containing products per month in Portugal.
Results: Two interruption periods were defined in the series: May 2011, when EMA announced it would review trimetazidine safety, and June 2012 to January 2013, when EMA announced it had reached a final opinion recommending restrictions; the European Commission approved EMA's recommendation; the Portuguese Medicines Authority issued safety alerts, changed the summary of product characteristics, and approved a direct health-care professional letter; and a regional bulletin was issued. Interruption 1 had no effect on trimetazidine use, but interruption 2 resulted in decreases in level and trend-from 8.3 million defined daily doses in 2010 to 2.8 million in 2015. After interruption 2, trimetazidine use tended towards a lower steady state.
Conclusions: There was a significant decrease in trimetazidine use in Portugal following a complex intervention that included safety alerts, changes to the summary of product characteristics, a direct health-care professional letter, and a regional drug bulletin. No effect was seen when EMA announced its review of trimetazidine safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pds.4585 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns.
Arch Toxicol
August 2024
Kolling Institute of Medical Research, Royal North Shore Hospital of Sydney, Sydney, NSW, 2065, Australia.
Article Synopsis
- * MDMA has been restricted in research due to its initial classification, but recent studies suggest its potential in treating PTSD, with the FDA and Australia moving toward allowing its therapeutic use.
- * Although it can have adverse effects, especially in party settings, deaths from MDMA alone are rare, often occurring when mixed with other substances, highlighting the need for better understanding and regulation.
Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?
Front Microbiol
October 2023
Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Introduction: The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) announced conditions for using recombinant human interleukin-1 receptor antagonist (rhIL-1ra) to treat hospitalized patients with Coronavirus disease 2019 (COVID-19) and risk for progression. These decisions followed publication of the suPAR-guided Anakinra treatment for Validation of the risk and early Management OF seveRE respiratory failure by COVID-19 (SAVE- MORE) phase 3 clinical trial that yielded positive results.
Methods: We conducted a literature review and theoretical analysis of IL-1 blockade as a therapy to treat COVID-19.
Evaluating the Effects of Rewards and Schedule Length on Response Rates to Ecological Momentary Assessment Surveys: Randomized Controlled Trials.
J Med Internet Res
October 2023
Physical Activity and Nutrition Determinants in Asia Programme, Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Article Synopsis
- Ecological momentary assessments (EMAs) are short surveys used to gather real-time data on participants' experiences, but their effectiveness can be limited by participant burden, which needs to be minimized for better response rates.* -
- The study analyzed the effects of different design features, including the method of communication (SMS vs. email) and varying reward structures, on EMA response rates in a cohort of university students over three survey bursts from April to October 2021.* -
- Results indicated that while changes to the reward structure did not improve response rates, extending the survey schedule from 7 days to 14 days significantly increased response rates, with overall higher rates observed in the second and third bursts of EMAs.*
Relationship Between Coronavirus Disease 2019 Vaccination Rates and Rare But Potentially Fatal Adverse Events: A Regression Discontinuity Analysis of Western Countries.
J Korean Med Sci
March 2023
Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Background: Owing to limited experience with the new vaccine platforms, discussion of vaccine safety is inevitable. However, media coverage of adverse events of special interest could influence the vaccination rate; thus, evaluating the outcomes of adverse events of special interest influencing vaccine administration is crucial.
Methods: We conducted regression discontinuity in time analysis to calculate the local average treatment effect (LATE) using datasets from Our World in Data and Johns Hopkins University Center for Systems Science and Engineering.
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
Orphanet J Rare Dis
March 2022
Children's Hospital, London Health Sciences Centre, London, ON, Canada.
Background: The Canadian government has committed to developing a national strategy for drugs for rare diseases starting in 2022. Considering this announcement, we conducted a comparative analysis to examine patient access to therapies for rare disease in Canada relative to Europe and the U.S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!